Shares of Augmedix, Inc. (OTCMKTS:AUGX – Get Free Report) were down 2.7% on Wednesday . The company traded as low as $0.74 and last traded at $0.75. Approximately 257,406 shares were traded during trading, a decline of 54% from the average daily volume of 558,973 shares. The stock had previously closed at $0.77.
Augmedix Trading Down 2.7 %
The company has a debt-to-equity ratio of 3.74, a quick ratio of 1.70 and a current ratio of 1.70. The company has a market cap of $36.73 million, a P/E ratio of -1.74 and a beta of -0.27. The stock has a 50-day moving average of $1.93 and a two-hundred day moving average of $3.75.
Augmedix (OTCMKTS:AUGX – Get Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.12) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.12). Augmedix had a negative return on equity of 980.09% and a negative net margin of 57.70%. The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.25 million. On average, equities research analysts predict that Augmedix, Inc. will post -0.48 earnings per share for the current year.
Augmedix Company Profile
Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.
Recommended Stories
- Five stocks we like better than Augmedix
- What is a Secondary Public Offering? What Investors Need to Know
- Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside
- Stock Dividend Cuts Happen Are You Ready?
- Campbell Soup Co. Targets Fiscal Q4 Stock Recovery
- How to invest in blue chip stocks
- Zebra Analysts Upgrade Stock, Forecasting Major Reversal
Receive News & Ratings for Augmedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Augmedix and related companies with MarketBeat.com's FREE daily email newsletter.